Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant Dimeglumine for Prevention of Chemotherapy-Induced Nausea and Vomiting
NCT05755659Unknown
- Sponsor
- Xijing Hospital
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Xijing Hospital. Primary endpoints: Safety of Fosaprepitant Dimeglumine at 7 days and Effectiveness of Fosaprepitant Dimeglumine at 7 days. Status: unknown.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05755659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755659.